More from Healthcare
Talk among a mammoth field of presidential candidates about drug price controls and an expansion of Medicare isn't helping biotech and health care stocks.
Insurance companies would have their claws in any potential new healthcare law so deep, the law will have slash marks on it.
Especially when healthcare CEOs discus political issues with analysts and reporters.
This health care selloff shows the value of diversification to protect our portfolios -- and to go on the offensive and find bargains.